Serological risk factors for concomitant interstitial lung disease in patients with idiopathic inflammatory myopathy

•High mortality of coexistence of ILD in patients with IIM.•Patients with interstitial lung disease had lower initial creatine kinase levels.•Patients with anti-Ro52 antibodies had 9.17-fold increased odds of ILD.•Patients with anti-Ro52 or anti-Jo1 antibodies had 13.44-fold increased odds of ILD.•T...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical neuroscience 2020-04, Vol.74, p.32-35
Main Authors: Huang, Hung-Ling, Lin, Wen-Chih, Yeh, Che-Chun, Sun, Yuan-Ting
Format: Article
Language:English
Subjects:
Anti-Jo1 antibody
Anti-Ro52 antibody
Dermatomyositis
Interstitial lung disease
Polymyositis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•High mortality of coexistence of ILD in patients with IIM.•Patients with interstitial lung disease had lower initial creatine kinase levels.•Patients with anti-Ro52 antibodies had 9.17-fold increased odds of ILD.•Patients with anti-Ro52 or anti-Jo1 antibodies had 13.44-fold increased odds of ILD.•The common serology tests can guide pulmonary screening for patients with IIM. Interstitial lung disease (ILD) is an extramuscular manifestation associated with increased mortality in idiopathic inflammatory myopathy (IIM). To identify risk factors for ILD in patients with IIM, this study retrospectively enrolled 117 eligible patients from a university medical center. After a comprehensive chart review, 56 patients were stratified into ILD (n = 28) and non-ILD (n = 28) groups. Clinical features, laboratory data, concomitant diseases, and serology profiles were compared. Patients with ILD had high prevalence of anti-Jo1 antibodies (p = 0.002), anti-Ro52 antibodies (p 
ISSN:0967-5868
1532-2653
DOI:10.1016/j.jocn.2020.01.060